CoChat

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Open access
Bravo, Lulu, Smolenov, Igor, Han, Htay Htay, Li, Ping, Hosain, Romana, Rockhold, Frank, Clemens, Sue Ann Costa, Roa, Camilo, Borja-Tabora, Charissa, Quinsaat, Antoinette, Lopez, Pio, López-Medina, Eduardo, Brochado, Leonardo, Hernández, Eder A, Reynales, Humberto, Medina, Tatiana, Velasquez, Hector, Toloza, Leonardo Bautista, Rodriguez, Edith Johana, de Salazar, Dora Ines Molina, Rodríguez, Camilo A, Sprinz, Eduardo, Cerbino-Neto, José, Luz, Kleber Giovanni, Schwarzbold, Alexandre Vargas, Paiva, Maria Sanali, Carlos, Josefina, Montellano, May Emmeline B, de Los Reyes, Mari Rose A, Yu, Charles Y, Alberto, Edison R, Panaligan, Mario M, Salvani-Bautista, Milagros, Buntinx, Erik, Hites, Maya, Martinot, Jean-Benoit, Bhorat, Qasim E, Badat, Aysha, Baccarini, Carmen, Hu, Branda, Jurgens, Jaco, Engelbrecht, Jan, Ambrosino, Donna, Richmond, Peter, Siber, George, Liang, Joshua, Clemens, Ralf · 2022 · The Lancet
Cited by 106

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccine SCB-2019. Methods This ongoing phase 2 and 3 double-blind, placebo-controlled trial was done in adults aged 18 years and older who were in good health or with a stable chronic health condition, at 31 sites in five countries (Belgium, Brazil, Colombia, Philippines, and South Africa). The participants were randomly assigned 1:1 using a centralised internet randomisation system to receive two 0·5 mL intramuscular doses of SCB-2019 (30 μg, adjuvanted with 1·50 mg CpG-1018 and 0·75 mg alum) or placebo (0·9% sodium chloride for injection supplied in 10 mL ampoules) 21 days apart. All study staff and participants were masked, but vaccine administrators were not. Primary endpoints were vaccine efficacy, measured by RT-PCR-confirmed COVID-19 of any severity with onset from 14 days after the second dose in baseline SARS-CoV-2 seronegative participants (the per-protocol population), and the safety and solicited local and systemic adverse events in the phase 2 subset. This study is registered on EudraCT (2020–004272–17) and ClinicalTrials.gov (NCT04672395). Findings 30 174 participants were enrolled from March 24, 2021, until the cutoff date of Aug 10, 2021, of whom 30 128 received their first assigned vaccine (n=15 064) or a placebo injection (n=15 064). The per-protocol population consisted of 12 355 baseline SARS-CoV-2-naive participants (6251 vaccinees and 6104 placebo recipients). Most exclusions (13 389 [44·4%]) were because of seropositivity at baseline. There were 207 confirmed per-protocol cases of COVID-19 at 14 days after the second dose, 52 vaccinees versus 155 placebo recipients, and an overall vaccine efficacy against any severity COVID-19 of 67·2% (95·72% CI 54·3–76·8), 83·7% (97·86% CI 55·9–95·4) against moderate-to-severe COVID-19, and 100% (97·86% CI 25·3–100·0) against severe COVID-19. All COVID-19 cases were due to virus variants; vaccine efficacy against any severity COVID-19 due to the three predominant variants was 78·7% (95% CI 57·3–90·4) for delta, 91·8% (44·9–99·8) for gamma, and 58·6% (13·3–81·5) for mu. No safety issues emerged in the follow-up period for the efficacy analysis (median of 82 days [IQR 63–103]). The vaccine elicited higher rates of mainly mild-to-moderate injection site pain than the placebo after the first (35·7% [287 of 803] vs 10·3% [81 of 786]) and second (26·9% [189 of 702] vs 7·4% [52 of 699]) doses, but the rates of other solicited local and systemic adverse events were similar between the groups. Interpretation Two doses of SCB-2019 vaccine plus CpG and alum provides notable protection against the entire severity spectrum of COVID-19 caused by circulating SAR-CoV-2 viruses, including the predominating delta variant. Funding Clover Biopharmaceuticals and the Coalition for Epidemic Preparedness Innovations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)00055-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 106

Metadata

Authors
Bravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsaat, A., Lopez, P., López-Medina, E., Brochado, L., Hernández, E. A., Reynales, H., Medina, T., Velasquez, H., Toloza, L. B., Rodriguez, E. J., de Salazar, D. I. M., Rodríguez, C. A., Sprinz, E., Cerbino-Neto, J., Luz, K. G., Schwarzbold, A. V., Paiva, M. S., Carlos, J., Montellano, M. E. B., de Los Reyes, M. R. A., Yu, C. Y., Alberto, E. R., Panaligan, M. M., Salvani-Bautista, M., Buntinx, E., Hites, M., Martinot, J.-B., Bhorat, Q. E., Badat, A., Baccarini, C., Hu, B., Jurgens, J., Engelbrecht, J., Ambrosino, D., Richmond, P., Siber, G., Liang, J., & Clemens, R.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-01
Volume
399
Issue
10323
Pages
461-472
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4206017004
Cited by
106
References
10
FWCI
11.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00055-1
The paper
Bravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsaat, A., Lopez, P., López-Medina, E., Brochado, L., Hernández, E. A., Reynales, H., Medina, T., Velasquez, H., Toloza, L. B., Rodriguez, E. J., . . . Clemens, R. (2022). Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)00055-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.